Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

NCT02717091 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Borderline Resectable Pancreatic Cancer

Interventions

DRUG: FOLFIRINOX
DRUG: gemcitabine + nab-paclitaxel

Sponsor

Nagoya University